Pharmacological preconditioning reduces myocardial infarct size in ischaemiareperfusion(I-R)injury.Dexmedetomidine,aselectiveα 2 -adrenoceptoragonist,hasa provencardioprotectiveeffectwhenadministeredpriortoI-R,althoughtheunderly- DexmedetomidinepreconditioningalleviatedmyocardialI-RinjuryinratsthroughinhibitionofinflammatoryprocessesassociatedwithdownregulationoftheHMGB1-TLR4-NF-κBsignallingpathwayviaactivationatα 2 -adrenergicreceptors.
Summary
Pharmacological preconditioning reduces myocardial infarct size in ischaemiareperfusion(I-R)injury.Dexmedetomidine,aselectiveα 2 DexmedetomidinepreconditioningalleviatedmyocardialI-RinjuryinratsthroughinhibitionofinflammatoryprocessesassociatedwithdownregulationoftheHMGB1-TLR4-NF-κBsignallingpathwayviaactivationatα 2 -adrenergicreceptors.
K E Y W O R D S
dexmedetomidine,highmobilitygroupbox1-toll-likereceptor4-nuclearfactorκB,myocardial protection,preconditioning Immuneandinflammatorypathwaysinitiatedbytheinnateimmunesys- tem have been implicated in myocardial ischaemia-reperfusion (I-R) injury.
| INTRODUCTION

1,2
Highmobilitygroupbox1(HMGB1)-ahighlyconservednuclear protein released from necrotic cells and secreted by activated macrophages,naturalkillercells,andmaturedendriticcells-hasbeenimplicated inmodulationofmyocardialI-Rinjury.
3-6
Inaddition,previousstudieshave shown that levels of HMGB1 in serumwere increased in patientswith acutemyocardialinfarctionandwereassociatedwithpooroutcomes.
7
Toll-like receptor 4 (TLR4) signalling has been implicated in cardiacdysfunctioninducedbyhaemorrhagicshockandhas,moreover, beenlinkedtotheproductionofproinflammatorymediatorsfollowing myocardialI-R. [8] [9] [10] IschaemiaisapotenttriggerforHMGB1release, andTLR4isaknownpathwayforHMGB1inapotentialfeed-forward mechanism. 5, 11 HMGB1 binds to TLR4, leading to the activation of downstream signalling molecules such as nuclear factor κB (NF-κB), therebypromotingthereleaseofproinflammatorycytokines,including tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6). 5, 12, 13 Therefore, these data indicate an important role of HMGB1-TLR4-
Dexmedetomidine, a selective α 2 -adrenoceptor agonist, offers good perioperative hemodynamic stability, reduced intraoperative anaesthetic requirements, and has proven anti-inflammatory effects.
14 Perioperative dexmedetomidine use is associated with decreasedpostoperativemortalityforupto1year,withdecreased incidence of postoperative complications and delirium in patients undergoingcardiacsurgery. 15 Moreover,dexmedetomidineshowed cardioprotective properties when administered prior to I-R events (dexmedetomidine preconditioning). 16, 17 A recent study demonstrated that dexmedetomidine mitigated the expression of several inflammatorymolecules,includingnitricoxide,TNF-α,interleukin-1β
(IL-1β),andIL-6,throughinhibitionoftheNF-κBsignallingpathway and activation of α 2 -adrenergic receptors. 18 Additionally, the study showedthatdexmedetomidineinhibitedtheexpressionofproinflammatorycytokines(TNF-αandIL-6)andHMGB1inserumaswellas thatofHMGB1mRNAinlungtissuesofmicewithsepsisinducedby cecalligationandpuncture(CLP). 19 Guetal. 
| RESULTS
| Myocardial function
| Expression of HMGB1-TLR4-NF-κB by western blot analysis
We detected HMGB1-TLR4-NF-κB expression in isolated left ventricles after 120minutes of reperfusion using western blot analysis.
Compared to the control group, I-R injury induced an increase in HMGB1-TLR4-NF-κB expression following 30minutes of ischaemia and 120minutes of reperfusion (P<.05). Dexmedetomidine significantly suppressed HMGB1-TLR4-NF-κB expression in isolated left ventricles (P<.05), but this was partially reversed by yohimbine, an α2-adrenergic receptor antagonist. Moreover, co-treatment with rHMGB1, enhanced HMGB1-TLR4-NF-κB activity, and this was partiallyreducedbydexmedetomidine(P<.05;Figure3A-D).
| Analysis of cytokine levels
Compared with the control group, I-R injury resulted in increased serum levels of TNF-α and IL-6 after 120minutes of reperfusion 
| Immunohistochemical analysis of HMGB1 and NF-κB
| DISCUSSION
In this study, we investigated the mechanisms underlying the cardioprotective properties of dexmedetomidine preconditioning, associated with the HMGB1-TLR4-NF-κB signalling pathway, in I-R.
DexmedetomidinepreconditioningalleviatedmyocardialI-Rinjuryin ratsbyinhibitingtheassociatedinflammatoryprocessthroughdownregulationoftheHMGB1-TLR4-NF-κBsignallingpathwaybyactiva-tionofα 2 -adrenergicreceptors.
Perioperativecardiaccomplicationssuchasmyocardialischaemia
and infarction are predominant causes of morbidity and mortality in patients undergoing noncardiac surgery.
21
Following an acute myocardial infarction, re-establishing coronary blood flow through rapid reperfusionstrategies,suchasthrombolysisorprimaryangioplasty,is essentialtosalvageviablemyocardialtissues.
22
However,reperfusion ofischaemicmyocardiumcarrieswithitaninherentriskthat,paradoxically,I-Rcouldcauselocalizedmyocardialinflammation,accompanied byapoptosis-aformofmyocardialcelldamage.
23
Agrowingbodyof evidence shows that inflammatory processes, including leukocyte recruitment, play a major role in the extension of myocardial damages afterI-R.
1,2,24
Studies have shown that HMGB1 functions as a proinflammatorycytokineandpromotesprogressionofmyocardialI-Rinjury. The present study showed that dexmedetomidine has cardioprotectivepropertieswhenadministeredpriortoI-Revents. Another study has shown that preconditioning with xylazine, an Ourstudyhassomelimitations.First,theexvivoisolatedheart model was established to investigate the effect of dexmedetomidineonglobalischaemia;however,thecreationofthismodelmay have evoked more severe damage to the heart than in an in vivo model. The dexmedetomidine concentrations used in this study werebasedonconcentrationsusedinclinicalsettings. 34 However, it would be difficult to extrapolate these data to humans becauseofinterspeciesdifferencesspecifictopharmacokineticsand pharmacodynamics.
In conclusion, dexmedetomidine preconditioning inhibited myocardialinflammationandprovidedmyocardialprotectionagainstI-R injuryinrats,partlybydownregulationoftheHMGB1-TLR4-NF-κB signalling pathway by activation of α 2 -adrenergic receptors. This studymayfacilitateanunderstandingofthespecificeffectsofdexmedetomidineontheheart,butwhileexcludingthecentralsympatheticeffects.
| METHODS
| Animals
Male adult Sprague-Dawley rats (8-10weeks old; 300-350g) were 
| Experimental protocols
Animals were anaesthetized with intraperitoneal (ip) chloral hydrate (400mg/kg) and heparinized with sodium heparin (1000U/ kg). A thoracotomy was performed and the heart was rapidly ex- 
| Western blot analysis
TheHMGB1-TLR4-NF-κBproteinlevelsweredeterminedbywest- 
| Cytokine analysis
Acommercialenzyme-linkedimmunosorbentassaykit(ELISA;Multi Science,Zhejiang,China)wasusedtodetectlevelsofTNF-αandIL-6 in the myocardium. Absorbance of standards and samples was determined by using spectrophotometry at 450nm with a microplate reader(MD190;MolecularDevices,Sunnyvale,CA,USA)andresults wereplottedagainstthelinearportionofthestandardcurve.
Furthermore,levels(IU/L)oflactatedehydrogenase(LDH)andcreatinekinase(CK)inCFafter120minutesofreperfusionwereanalyzed usingcommercializedassaykits(A032andA020-2;NanjingJiancheng BioengineeringInstitute,Nanjing,China).
| Immunohistochemical analysis
ThelocalizationofHMGB1andNF-κBwasdeterminedbyimmunohis-tochemical analysis. After reperfusion, hearts were fixed in 4% formal- 
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